Exact sciences corporation stock.

Sep 9, 2023 · Exact Sciences' revenue has grown rapidly in the past five years, but the bottom line hasn't made much progress. Cologuard 2.0 should help the company's top line maintain its momentum. Exact ... Globally, the cancer diagnostics market was worth $172.3 billion in 2022, according to analysts from Grand View Research. And by 2030, they project that will rise to $293.5 billion, averaging a ...Sentiment. Exact Sciences (EXAS) has an AI Score of /10 (Buy) because its overall probability of beating the market (S&P 500) in the next 3 months (43.63%) is +42.63% vs. the average probability (%) of US stocks analyzed by our Artificial Intelligence. The AI-powered overall analysis of Exact Sciences (EXAS) is based on the fundamental ...May 9, 2023 · MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS ), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of ... Estimate Trend. In the past 60 days, the Zacks Consensus Estimate for Exact Sciences’ loss for 2023 has moved 25% north to $2.16. The Zacks Consensus Estimate for 2023 revenues is pegged at $2. ...

MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the …Exact Sciences' valuation has been plummeting. In 2022, shares of Exact Sciences fell 36%, underperforming the S&P 500, which declined by 19%. Exact Sciences isn't near its 52-week low of $29.27 ...Exact Sciences Corp. is a molecular diagnostics company specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer, in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer. Since then Exact Sciences has grown its product portfolio to ...

The Exact Sciences Corp NASDAQ: EXAS stock price reached the ceiling this week, with shares gaining a sizable 16.38% over the past five days. Most of that value climb came yesterday, with the molecular diagnostic company's stock gaining 24.65% at the end of the trading session. Putting this figure into perspective is that the S&P 500 finished ...The number of shares outstanding of the Registrant’s $0.01 par value Common Stock as of February 20, 2023 was178,217,142. ... EXACT SCIENCES CORPORATION ANNUAL REPORT ON FORM 10‑K YEAR ENDED DECEMBER 31, 2022 TABLE OF CONTENTS Page No. Part I Item 1. Business 4 Item 1A. Risk Factors 19

Exact Sciences Corp. Presents Multiple Studies At San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients CI Nov. 29: Transcript : Exact Sciences Corporation Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-29-2023 12:30 PM29-Jul-2019 ... Exact Sciences Corporation (EXAS) shares fell more than 7% during Monday's session after the company announced a $2.8 billion deal to ...Exact Sciences Corp. completed the acquisition of Thrive Earlier Detection Corp. in a cash and stock deal valued at up to $2.15 billion. Under the previously disclosed terms of the deal, Thrive's shareholders were to receive $1.7 billion at closing, consisting of 65% in Exact Sciences common stock and 35% in cash. Thrive would also be eligible ...MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended March 31, ... Represents stock-based compensation expense and 401(k) match expense as the …Get EXACT Sciences Corporation (EXAS) share price today, stock analysis, price valuation, performance, fundamentals, market cap, shareholding, and financial ...

May 9, 2023 · MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS ), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of ...

Oct 19, 2023 · "Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ...

Complete Exact Sciences Corp. stock information by Barron's. View real-time EXAS stock price and news, along with industry-best analysis.Exact Sciences Corp. is a molecular diagnostics company specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer, in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer. Since then Exact Sciences has grown its product portfolio to ...Exact Sciences (EXAS) delivered earnings and revenue surprises of 46.84% and 11.06%, respectively, for the quarter ended March 2023. ... is selling $2 billion of stock in Las Vegas Sands Corp. so ...Our mission at Exact Sciences is to eradicate cancer and the suffering it causes — through tests that help prevent it, detection that finds it earlier, and guidance for its successful treatment. Our TestsExact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on …

Exact Sciences Company Info. EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non ... According to 15 stock analysts, the average 12-month stock price forecast for Exact Sciences stock is $92.07, which predicts an increase of 39.52%. The lowest target is $73 and the highest is $130. On average, analysts rate Exact Sciences stock as a strong buy.Cologuard uses a biomarker panel which analyzes a person’s stool sample for 10 DNA markers, as well as blood in the stool (hemoglobin). This multi-marker approach is a distinguishing feature of Exact Sciences’ scientific platform. Cologuard finds colon cancer even in early stages when it is more treatable. 1,2,3* Cologuard is convenient. Negative. Nikkei 225. 33,451.83. +0.29%. Positive. Source: LSEG - data delayed by at least 15 minutes. Get Exact Sciences Corp (EXAS.A) real-time stock quotes, news, price and financial ...Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests.

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present new data supporting the company's research in early cancer ...The average of price targets set by Wall Street analysts indicates a potential upside of 51.7% in Exact Sciences (EXAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. Find the latest Exact Sciences Corporation (EXAS ...

Ordinary share capital refers to shares that are issued by a company that allow shareholders voting rights within a corporation. Ordinary shareholders may also receive dividends. Ordinary shares are also referred to as common stocks.Exact Sciences Corporation (EXAS.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Exact Sciences Corporation ...10-Jan-2023 ... The most important factor in Exact Sciences' business outlook is its commitment to developing innovative new technologies that improve cancer ...Stock EXAS November 21, 2023 NASDAQ 20 minutes delay ... At Exact Sciences, our mission is to eradicate cancer and the suffering it causes — through tests that help prevent it, detect it earlier ...Buy Exact Sciences Corporation Shares from India at $67.03 (0 Commission) today. Start investing in Exact Sciences Corporation stocks from India now with fractional investing only on INDmoneyappGet the latest Exact Sciences Corporation (EXAS) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.Exact Sciences Corporation completed the acquisition of Omicera Diagnostics Gmbh for $19.41 million on May 2, 2022. As part of the acquisition, Exact Sciences issued 265,186 common shares, contingent consideration of $4.6 million, Working capital adjustment to be settled in cash of $0.016 million and maximum of $6 million of additional cash ...Company profile page for Exact Sciences Corp including stock price, company news, executives, board members, and contact information26-Apr-2022 ... MADISON, Wis., April 26, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended ...

© Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI 53719 Powered By Q4 Inc. 5.111.2.6 5.111.2.6

Stock Information · Financial Information · SEC Filings · Quarterly Results ... © Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI 53719. Powered By ...Complete Exact Sciences Corp. stock information by Barron's. View real-time EXAS stock price and news, along with industry-best analysis. MADISON - Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it has filed a lawsuit against Geneoscopy, Inc. in the United States District Court for the District of Delaware. The lawsuit seeks damages and a court order to stop Geneoscopy from making, using, selling, or …Aug 2, 2022 · Under the terms of the asset purchase agreement, mdxhealth acquired the Oncotype DX GPS prostate cancer business of Exact Sciences for an aggregate purchase price of up to $100 million, of which ... MADISON, Wis., Feb. 21, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $553.0 million for the fourth quarter of 2022 and $2,084.3 million for the full year of 2022, both ended Dec. 31, 2022.On November 30, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $64.00 per share. One-month return of Exact Sciences Corporation …Exact Sciences Corporation (EXAS.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Exact Sciences Corporation ...22-Feb-2022 ... MADISON, Wis., Feb. 22, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that ...Our mission at Exact Sciences is to eradicate cancer and the suffering it causes — through tests that help prevent it, detection that finds it earlier, and guidance for its successful treatment. Our TestsMADISON, Wis., May 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is ...

Nov 13, 2023 · Exact Sciences Corp’s trailing 12-month revenue is $2.4 billion with a -11.7% profit margin. Year-over-year quarterly sales growth most recently was 20.1%. Analysts expect adjusted earnings to reach $-1.363 per share for the current fiscal year. Exact Sciences Corp does not currently pay a dividend. Analyst Recommendations on Exact Sciences Corporation. Goldman Sachs Adjusts Price Target on Exact Sciences to $90 From $100, Keeps Buy Rating. Nov. 03. MT. BofA …The Exact Sciences Corp NASDAQ: EXAS stock price reached the ceiling this week, with shares gaining a sizable 16.38% over the past five days. Most of that value climb came yesterday, with the molecular diagnostic company's stock gaining 24.65% at the end of the trading session. Putting this figure into perspective is that the S&P 500 finished ...Instagram:https://instagram. aetna dental reviewsbest iphone insurance planscrybf stockcrispr stock quote Shares Held % O/S Share Change Filing Date; The Vanguard Group, Inc. 17,175: 9.52: 164: 06/30/2023: JPMorgan Investment Management, Inc. 12,307: 6.82: 878: 06/30/2023 1 dollar 1979 coin5 yr treasury yield Our pipeline team is responsible for advancing our future tests and developing life-changing cancer diagnostics to help patients throughout the course of their diagnosis and treatment. opec oil production Exact Sciences Corporation completed the acquisition of Omicera Diagnostics Gmbh for $19.41 million on May 2, 2022. As part of the acquisition, Exact Sciences issued 265,186 common shares, contingent consideration of $4.6 million, Working capital adjustment to be settled in cash of $0.016 million and maximum of $6 million of additional cash ...Exact Sciences EXAS Operating Losses;.Another 70% to Fall!! The EXAC chart has been a downtrend from $130 to $40 with a High VOLUME. The stock is making new bottoms while insiders and the executive team have constantly been selling at any price! The stock is down 70% from its high of $137!intraday 1w 1m 6m ytd 1y 3y 5y max Mountain-Chart Compare with Compare with up to 5 Stocks On Wednesday 11/29/2023 the closing price of the EXACT …